1. Medicines
  2. Ophthalmology
  3. ▼ BEOVU® (brolucizumab)

Prescribing information

 

▼ Beovu® (brolucizumab)

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Beovu is indicated in adults for the treatment of neovascular (wet) AMD.1

recommended by nice

reviewed by smc

 

AMD, age-related macular degeneration; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium.

References

  1. Beovu Summary of Product Characteristics, 2020.
  2. National institute for Health and Care Excellence (2021) Brolucizumab for treating wet age-related macular degeneration (NICE guideline 672). Available at https://www.nice.org.uk/guidance/ta672. [Accessed 7 June 2021].
  3. https://www.scottishmedicines.org.uk/medicines-advice/brolucizumab-beovu-full-smc2272/  [Accessed 7 June 2021].
Rate this content: 
No votes yet
UK | June 2021 | 122410
Ophthalmology
Product
Print
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]